glp 1 noom Unboxing GLP-1ᴿˣ Noom Unveils Microdose GLP-1 Program
Description
Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and lymphomas bearing wild-type TP53
doi:10.1021/acs.jmedchem.9b01071 14
Since estrogen fuels endometriosis lesion activity, this pathway may be relevant for women whose disease is influenced by obesity or estrogen excess
, & Fodor, D
While further research is warranted, current evidence supports their use as promising interventions to improve metabolic health beyond mere weight loss
